In addition to the promising use of C15:0 to prevent ferroptosis and downstream AD pathology, in the current study, C15:0 had two dose-dependent inhibitory activities that were detected using the Eurofins Discovery Alzheimer’s LeadHunter MoA Panel: inhibition of fatty acid amide hydrolase (FAAH) and monoamine oxidase B (MAO-B). Here, MAOB is linked to Alzheimer disease.